

Medical Oxygen

Medical oxygen is a lifesaving medicine with no substitute. It is used to treat a broad spectrum of illnesses and conditions, including pneumonia, COVID-19, advanced HIV disease, severe tuberculosis (TB) and malaria, and is vital for maternal and child health services, surgery and critical care.

Despite its importance, medical oxygen is often unavailable where needed most. Fewer than 50% of health facilities in many low- and middle-income countries have uninterrupted access to oxygen, with the largest gaps found across sub-Saharan Africa and Asia.

Inadequate health care infrastructure, lack of oxygen-related equipment, and prohibitively high costs are some of the challenges limiting access to medical oxygen. The COVID-19 pandemic exacerbated these shortages. In early 2021 the need for medical oxygen rose tenfold in just a few weeks; many hospitals ran out of medical oxygen, leaving patients without lifesaving treatment and leading to countless preventable deaths.

How we work

At Unitaid, we save lives by making new health products available and affordable for people in low- and middle-income countries. We identify innovative treatments and tools, help tackle the

market barriers that are holding them back, and get them to the people who need them most – fast.

Equitable, sustainable access to medical oxygen is key to improving maternal and child health, strengthening primary health care in support of universal health coverage, and to ensuring health systems are better prepared for the next global health emergency. When the COVID-19 pandemic exposed broad failures in access to medical oxygen, we built on our existing work to address acute needs and support more sustainable access.

Responding to global health emergencies:

In response to the COVID-19 pandemic, we immediately provided flexible financing and delivered emergency oxygen supplies to 51 low- and middle-income countries. We also played a leading role in the Access to COVID-19 Tools Accelerator (ACT-Accelerator), a groundbreaking collaboration to ensure equitable access to COVID-19 vaccines, tests and treatments. As co-lead of the ACT Accelerator's Therapeutics Pillar, together with the Global Fund to Fight AIDS, Tuberculosis and Malaria and Wellcome, we launched the Oxygen Emergency Taskforce to address the critical shortage of oxygen in the fight against the pandemic. The taskforce raised more than US\$1 billion to boost access to medical oxygen, expand production, negotiate for better pricing, and provide technical advice to governments.



Photo: Djeneba Mariko, 17 months old, was treated with oxygen therapy for severe malaria, anemia and respiratory distress at the pediatric unit of the Centre de Santé de Références in Dioila, Mali. © Seyba Keita/ ALIMA.

Through unprecedented agreements with two major gas companies, we secured price reductions of approximately 22% for liquid oxygen and 43% for cylinders and cylinder filling, paving the way for long-term agreements for access to liquid oxygen.

Improving child survival: Children with hypoxemia – dangerously low levels of oxygen in the blood – and respiratory distress need immediate diagnosis and oxygen therapy. Yet most children in low- and middle-income countries lack access to effective tests and treatment; for example, of the 7.2 million children with pneumonia in critical need of medical oxygen each year, studies have shown that only one in five children will receive it. To improve child survival, we are working to speed up the availability, adoption and scale-up of new tools to improve oxygen delivery and respiratory support, suitable for use in low-resource settings.

For example, two initiatives that we are implementing with our partners ALIMA (the Alliance for Medical Action) and PATH are examining the feasibility, cost-effectiveness and impact of introducing pulse oximeters, a device used to measure the oxygen saturation in the blood to diagnose severe hypoxemia. Because they are portable and noninvasive, pulse oximeters are particularly suitable for use with children at the primary care level.




Only one in five children with pneumonia in critical need of medical oxygen receive it

Together with Vayu Global Health, we also helped bring to market two new devices that enable newborns and young children to access oxygen therapy: an oxygen blender – a machine used to deliver the right amount of oxygen to patients that prevents the eye, lung and brain damage associated with giving young children a pure oxygen supply; and a bubble continuous positive airway pressure (bCPAP) device – a non-invasive way of ventilating newborns who are struggling to breathe. These potentially game-changing devices are low-cost, easy to use and don't need an electricity supply or compressed air, unlike the existing products on the market. Over 400,000 babies across 41 countries, including conflict-affected countries like Ukraine, Sudan, South Sudan, and DRC have been treated with Vayu Health's bCPAP system. This device is manufactured in Kenya, supporting local economies while also building regional capacity to produce essential medical equipment. Already, lifesaving treatment with a Vayu device is initiated every 2 minutes. We are working with partners and donors to scale up production and use of these devices even further across these and other low- and middle-income countries.

Building alliances and strengthening pandemic preparedness:

Unitaid is investing in sustainable oxygen production and delivery systems to ensure countries are better prepared for future health emergencies and everyday medical needs alike, building on lessons from the COVID-19 pandemic. For example, through the [East African Program on Oxygen Access](#), we're working with the Clinton Health Access Initiative (CHAI), MedAccess, and oxygen producers in Kenya and Tanzania to scale up the production of medical-grade liquid oxygen. What sets this initiative apart is that it's driven by local companies – they will build and operate the new oxygen plants themselves. This will make supply more affordable and reliable, while also strengthening the region's ability to respond to future health threats. We're currently exploring options with our partners to expand this model into West and Central Africa.



To continue the critical work on medical oxygen, the Oxygen Emergency Taskforce evolved into the Global Oxygen Alliance (GO2AL) – a broader partnership that includes more than 20 health partners and representatives from civil society and affected communities. Co-chaired by Unitaid and the Global Fund, GO2AL aims to convert the investments made during the pandemic into lives saved, including financing to expand production, lowering the price of oxygen and providing technical support to governments. GO2AL collaborates across members and other partnerships to strongly position and advocate for sustainable oxygen systems as a building block for health system strengthening, universal health coverage and pandemic prevention, preparedness and response.

In February 2025, the Lancet Global Health Commission on Medical Oxygen Security released its landmark report, [Reducing global inequities in medical oxygen access](#). The Commission, launched in 2022 with support from Unitaid and other partners, highlights that over 5 billion people lack reliable access to safe, affordable medical oxygen. It calls for coordinated global investment and long-term systems approaches to ensure medical oxygen is embedded as an essential component of resilient health systems.

Our impact

Working closely with governments, industry, health providers and global health partners, we achieved impact in two ways: firstly, we delivered oxygen to help meet surge demand during the COVID-19 pandemic; secondly, we contributed to health system strengthening through market shaping, technical support and essential infrastructure

development to build resilience and increase long term access to oxygen, thus saving millions of lives in the future. Together with our partners, we have:

- **Delivered emergency oxygen supplies to respond to COVID-19:** We provided more than 26,000 cylinders, 52,000 concentrators and 14,000 pulse oximeters, and installed, procured or repaired 53 pressure swing adsorption plants (PSA).
- **Increased long-term stability of oxygen supply and equipment:** We secured unprecedented agreements with two major industrial liquid gas companies, leading to price reductions of 22% for liquid oxygen and 43% for cylinders and cylinder filling and paving the way to long-term sustainability of supply. We negotiated, or are negotiating, over 40 agreements linked to liquid oxygen supply and PSA repairs.
- **Provided technical support and strengthened local capacity of health systems to provide oxygen therapy:** We supported the training of over 17,500 clinical and biomedical staff and the development of national guidelines and training materials in seven countries.
- **Introduced innovative, cost-effective oxygen-delivery products that are designed for use in low-resource settings:** We helped bring to market an oxygen blender and a bubble continuous positive airway pressure device for newborns and we are testing the effectiveness and impact of new pulse oximeters.

The long-term benefits of our work will have a huge impact: For example, strengthening oxygen systems could reduce hospital-based pediatric pneumonia deaths by nearly half and overall pediatric hospital deaths by a quarter. Building more sustainable and robust oxygen ecosystems will be crucial to achieving universal health coverage and global pandemic prevention, preparedness and response goals.



Case Study:

Supplying oxygen, saving lives

Leoncio Carrión was gasping for air when he arrived at the Rosa Sanchez de Santillan Hospital in Ascope, a small town in Peru. Battling pulmonary fibrosis, a lung disease that damages lung tissue, the 78-year old was lucky; if he had come just weeks earlier, he may not have survived. But the hospital had just acquired a lifesaving resource: medical oxygen. The oxygen was supplied by an oxygen plant newly repaired by engineers with Partners In Health through BRING 02, a Unitaid-funded initiative to accelerate access to safe, reliable, and quality oxygen in Lesotho, Madagascar, Malawi, Peru and Rwanda. Before the repair work began, the oxygen plant at the hospital was rundown, leaving Ascope with virtually no access to medical oxygen. The shortage worsened during the COVID-19 pandemic. “Having medical oxygen available 24 hours a day means having the possibility of saving lives,” said Dr. Luis Cáceres, a doctor at the hospital. “We all deserve to receive the best health care and delivery, with quality and equal opportunity.” Our investment facilitated the repair of 20 oxygen plants across Peru and the training of staff in how to operate and maintain the equipment. Now, the hospital has a fully operational oxygen plant that serves the hospital, the 15 health centers and emergency response teams who rely on it to refill oxygen tanks, and patients like Carrión who use oxygen at home.

“I feel calmer and safer,” said Carrión. “Thank God, now the Rosa Sanchez de Santillan Hospital has an oxygen plant that allows me to continue living.”

Photo: Leoncio Carrión is one of hundreds of patients who have accessed lifesaving oxygen therapy in Ascope, Peru after oxygen plant repairs funded by Unitaid. © José Luis Diaz Catire/Partners In Health.



Looking ahead

The COVID-19 pandemic highlighted the critical role medical oxygen plays in treating severe illness – and the deadly consequences of shortages. Medical oxygen is essential for improving child survival, improving quality of care for COVID-19, treating severe malaria, TB and advanced HIV, and preparing for future pandemics. The world cannot afford to continue to underinvest in this essential medicine. While global health partners and governments have made great progress in increasing affordability, access and supply of medical oxygen as part of the global response, this work must continue. Without continued investment, we risk facing the same challenges in the next pandemic.

Moving forward, Unitaid is identifying opportunities to expand access through innovation – testing new generation technologies such as Medical Ceramic Oxygen Generators (M-COG) and Corrugated Medical Tubing (CMT) to assess how they can improve reliability and reach. We are also piloting business models that ease the burden of maintaining complex respiratory equipment, ensuring it remains functional and available where needed. Our ongoing investments will continue to shape markets, drive adoption, and promote sustainable, cost-effective oxygen access worldwide.

About Unitaid:

We save lives by making new health products available and affordable for people in low- and middle-income countries. We work with partners to identify innovative treatments, tests and tools, help tackle the market barriers that are holding them back, and get them to the people who need them most – fast. Since we were created in 2006, we have unlocked access to more than 100 groundbreaking health products to help address the world’s biggest health challenges, including HIV, TB, and malaria; women’s and children’s health; and pandemic prevention, preparedness and response. Every year, more than 300 million people benefit from the products we’ve helped roll out.